Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2021 Q2- Text added to 2021 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
New words:
Abraxane, adenocarcinoma, administer, America, atezolizumab, bevacizumab, breakthrough, cadence, Canada, de, deadly, denial, discontinued, ductal, environment, exploration, facilitation, feedback, footprint, Foundation, gemcitabine, GOG, Gynecological, impossible, label, moderately, mPDAC, Network, North, paclitaxel, percentage, Roche, shortage, sponsor, unable
Removed:
booked, deposit, improvement, June
Valuein 2021 Q2 filing- Value in 2021 Q3 filing
Original filings
Filing view